Bristol Myers Squibb Gets A Second Hit In Pulmonary Fibrosis
Executive Summary
Phase III trials of BMS-986278 are already being prepped.
You may also be interested in...
BMS Trumpets Breakthrough For Phase III-Bound IPF Drug
Bristol Myers Squibb believes LPA1 receptor inhibition is the best approach to meet the urgent need for well tolerated new pulmonary fibrosis treatment options that can improve symptoms and address the underlying cause of disease.
A Look Into The Future Of NASH
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
Taking On Obesity The Hard Way
Despite the astounding efficacy and commercial potential of incretins in obesity, many groups are trying different mechanistic approaches to the disease – if only to enable combinations.